FINWIRES · TerminalFinancial News · Live TerminalLIVE

SHE:002653

25 stories mentioning SHE:002653Updated 18d ago

Every FINWIRES story that references SHE:002653, newest first.

What's the latest news on SHE:002653?

Haisco Pharmaceutical's Attributable Profit Expands Fivefold in H1

Haisco Pharmaceutical's (SHE:002653) attributable profit ballooned 427%, or about 5.3 times, to 851.2 million yuan in the first half from 161.5 million yuan, after adjustments, in the year-ago period, according to a Thursday filing with the Shanghai/Shenzhen Stock Exchange.Earnings per share at the drug company expanded to 0.7601 yuan from 0.1442 yuan in the prior-year period.Operating revenue grew 55% year over year to 3.10 billion yuan from 2.00 billion yuan.Directors declared a dividend of 5.26 yuan per 10 shares, or 0.526 yuan per share.

Haisco Grants Licensing Rights to US-Based Sentivera for Anti-Inflammatory Drug

Haisco Pharmaceutical (SHE:002653) granted exclusive licensing rights to US-based Sentivera Therapeutics to develop and commercialize the Chinese-listed drug company's independently developed preclinical innovative drug for inflammatory diseases globally, excluding mainland China, Hong Kong, Macau, and Taiwan.The total licensing deal will reach more than $1.5 billion, with Sentivera paying Haiso an upfront consideration of $75.9 million, comprising $40 million in cash and nearly 12 million shares in Sentivera for $35.9 million, or a 17.5% equity, according to a Wednesday filing with the Shenzhen bourse.The amount also consists of up to $1.46 billion in development, regulatory, and commercial milestone payments and royalties on post-launch net sales of mid-single-digit to low-double-digit levels, Haisco said.Company shares rose 2% during afternoon trading on Wednesday.

Haisco Pharma Gets China Nod for HSK47388 Psoriatic Arthritis Trial; Shares Down 4%

Haisco Pharmaceutical (SHE:002653) received approval from China's National Medical Products Administration to conduct clinical trials for HSK47388 Tablets (I) in psoriatic arthritis, according to a Shenzhen bourse filing on Wednesday.The drug was previously approved to enter clinical trials for psoriasis and inflammatory bowel disease.The Chinese pharmaceutical company's shares were down nearly 4% in midday trade.

Haisco Pharmaceutical Gets China Nod for Analgesic Drug Trial; Shares Down 4%

Haisco Pharmaceutical (SHE:002653) obtained approval from China's drug regulator to conduct clinical trials for its HSK51155 tablets.The oral drug candidate is being developed for the treatment of pain-related conditions, according to a filing with the Shenzhen bourse on Wednesday.Shares of the company were down nearly 4% in recent trade.

Haisco Pharmaceutical Gets China Clinical Trial Nod for Anti-Inflammatory Tablets

Haisco Pharmaceutical (SHE:002653) received clinical trial approval from China's National Medical Products Administration for its self-developed HSK60002 tablets, indicated for inflammatory diseases, according to a Thursday filing with the Shenzhen bourse.Shares rose 1% during morning trading on Thursday.

Treasury38d ago

Strong Exports Drive China Shares Higher; Haisco Pharmaceutical Up 4%

Chinese shares rose at the end of Friday's trade as the country's exports topped forecasts.The Shanghai Composite Index, the main gauge of Chinese stocks, closed 1.0% higher to 3,940.04. The Shenzhen Component Index rose 1.4% to 14,311.01.China's exports rose 23.9% year over year to $397.9 billion in July, beating Reuters' forecast of a 22.2% growth. Meanwhile, imports rose 27.5% to $285.4 billion, lower than Reuters estimates of 27.9%.Trade surplus narrowed to $112.5 billion in July from $125.62 billion in June, higher than the consensus forecast of $109.4 billion tracked by Investing.com.On the regulatory front, the People's Bank of China is adding more gold reserves in Hong Kong over the past few months. PBOC's move is seen to help the city become a bullion trading hub and also fuels a trend of returning its gold reserves to Hong Kong from London.In company news, Haisco Pharmaceutical (SHE:002653) received clinical trial approval from China's National Medical Products Administration for its self-developed HSK51155 tablets for controlling migraine pain. Also, the company will provide up to 261 million yuan in loans to its holding subsidiary Haisijinuo for research and development and working capital. Shares of the pharmaceutical company closed 4% higher Friday.

Shanghai Composite^SZSESHE:002653

Haisco Pharmaceutical Backs Subsidiary With 261 Million Yuan Loan; Shares Up 4%

Haisco Pharmaceutical (SHE:002653) will provide up to 261 million yuan in loans to its holding subsidiary Haisijinuo for research and development and working capital.The five-year facility carries a 3.05% annual interest rate, with minority shareholder Hailikesi contributing 30 million yuan on pro rata terms, according to a Friday filing with the Shenzhen bourse.Shares of the pharmaceutical company rose nearly 4% in recent trade.

Haisco Pharmaceutical Gets China Clinical Trial Nod for Migraine Treatment; Shares Rise 4%

Haisco Pharmaceutical (SHE:002653) received clinical trial approval from China's National Medical Products Administration for its self-developed HSK51155 tablets, according to a Friday filing with the Shenzhen bourse.HSK51155 is indicated for pain control for migraines, according to the filing.In April, Haisco entered into a cooperation agreement allowing AbbVie Group Holdings to develop, manufacture, and commercialize the drug globally except in mainland China, Hong Kong, and Macau, with a potential transaction value topping $700 million, the company said.Shares rose 4% during the midday break on Friday.

Haisco Pharmaceutical Gets Nod for Marketing of Iptacopan Succinate Tablets; Shares Up 4%

Haisco Pharmaceutical (SHE:002653) received approval from China's National Medical Products Administration for the marketing of the iptacopan succinate tablets, according to a Thursday disclosure on the Shenzhen bourse.The drug will be used for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria.The pharmaceutical company's shares jumped 4% during the afternoon trade.

Haisco Pharmaceutical Raises 1.23 Billion Yuan Via Share Placement

Haisco Pharmaceutical (SHE:002653) raised net proceeds of 1.23 billion yuan via a private placement of 21.0 million shares at 59.37 yuan apiece.CITIC Securities served as lead underwriter, according to a Thursday filing with the Shenzhen bourse.

Haisco Pharmaceutical Gets China IND Application Acceptance for Novel Inflammatory Drug

Haisco Pharmaceutical (SHE:002653) said China's medical products regulator has accepted its investigational new drug application for HSK60002 tablets.The drug was independently developed for treating inflammatory diseases, according to a Tuesday filing with the Shenzhen bourse.Shares of the company slid 1% in recent trade.

Haisco Pharmaceutical's China IND Application for Novel Inflammatory Drug Accepted

Haisco Pharmaceutical (SHE:002653) said China's medical products regulator has accepted the investigational new drug application for HSK60002 tablets.The drug was independently developed for treating inflammatory diseases, according to a Tuesday filing with the Shenzhen bourse.Shares of the company fell 1% in recent trade.

Haisco Pharmaceutical Gets China Approval for Pain Relief Capsules

Haisco Pharmaceutical (SHE:002653) received approval from China's National Medical Products Administration for its crisugabalin besilate capsules, according to a Tuesday filing with the Shenzhen bourse.The drug helps treat neuropathic pain in adults.Shares fell over 2% during the midday break on Tuesday.

Haisco Pharma's H1 Profit to Skyrocket to Up to 575%; Shares Up 3%

Haisco Pharmaceutical (SHE:002653) expects its net profit attributable to shareholders in the first half to skyrocket by between 513% and 575% to a range of 790 million yuan to 870 million yuan, according to a Shenzhen bourse filing on Thursday.The attributable profit a year earlier was 128.8 million yuan.Earnings per share are expected to be between 0.71 yuan and 0.78 yuan, higher than the previous year's EPS of 0.12 yuan.The forecast was attributed to the growth of drug sales and an increase in licensing revenue after entering into multiple out-licensing agreements.The pharmaceutical company's shares rose 3% during the midday trade.

Haisco Pharmaceutical's Stock Fluctuates 20% for Three Straight Trading Days

Haisco Pharmaceutical's (SHE:002653) stock fluctuated by a total of 20% over three straight trading sessions from June 29 to July 1, according to a Thursday filing with the Shenzhen bourse.The drug company said its operations are normal and did not flag any reason for the stock fluctuation.Shares rose 2% during afternoon trading on Thursday.

Haisco Pharma Gets Nod to Trial HSK46256 Tablets; Shares Up 3%

Haisco Pharmaceutical (SHE:002653) received approval from China's National Medical Products Administration for the clinical trials of HSK46256 tablets, according to a Shenzhen bourse filing on Friday.The drug was developed as a treatment for advanced solid tumors.The Chinese drug company's shares rose 3% during the morning trade.

Chinese Regulator Approves Haisco Pharmaceutical's Non-Opioid Pain Reliever

Chinese drug regulators approved Haisco Pharmaceutical Group's (SHE:002653) HSK51155 tablets, according to a Wednesday filing with the Shenzhen bourse.The pain reliever, a non-opioid analgesic, is seen to reduce adverse reactions and addiction risks, the company said in its filing.

Haisco Pharmaceutical to Sign Licensing Agreement with Eli Lilly

Haisco Pharmaceutical (SHE:002653) subsidiary Haisco Pharmaceutical Technology (Lhasa) and Eli Lilly will sign a licensing and research collaboration agreement for five experimental drug projects, according to a Tuesday filing with the Shenzhen bourse.Eli Lilly will obtain global exclusive rights to the projects, except in China, Hong Kong, Macau, and Taiwan, which Haisco will handle.Haisco will be entitled to up to $87 million in upfront payments for five target projects from nomination to candidate compound confirmation, as well as up to $2.97 billion after achieving clinical, regulatory, and commercialization milestones.The Chinese drug company will also receive single-digit tiered royalties on future product sales, Haisco said in a separate press release.

Haisco Pharma Gets Nod to Trial HSK44459 Cream

Haisco Pharmaceutical (SHE:002653) obtained approval from China's National Medical Products Administration for the clinical trials of the HSK44459 cream, according to a Wednesday filing on the Shenzhen bourse.The cream will be tested as a treatment for psoriasis and atopic dermatitis.

Haisco Pharmaceutical Q1 Profit Up 1,090%, Revenue Jumps 75%

Haisco Pharmaceutical (SHE:002653) posted first-quarter attributable net profit of 554.6 million yuan, up 1,090% from 46.6 million yuan the previous year.Earnings per share climbed to 0.50 yuan from 0.04 yuan, according to a weekend filing on the Shenzhen bourse.Operating revenue jumped 75% year over year to 1.56 billion yuan from 892.0 million yuan.Shares of the pharmaceutical company rose 2% in recent trade.

Showing 1-20 of 25

Track with the FINWIRES app suite

Track SHE:002653 in your portfolio

Analyze SHE:002653 options with the wheel strategy

See market sentiment on SHE:002653